Broadridge Financial Solutions, Inc.

(New York Stock Exchange)

Broadridge Financial Solutions (BR) stock at a glance

Full Broadridge Financial Solutions report
Ticker
BR
Exchange
New York Stock Exchange
News sentiment ยท last 30 days
+50 Somewhat Bullish โ–ฒ +30 vs. previous 30 days
30-day average of 12 articles ยท scale โˆ’100 to +100

Across 12 scored articles from Oct 16 to Nov 14, 2026 (UTC), the average sentiment of Broadridge Financial Solutions news is Somewhat Bullish (+50) on a scale from โˆ’100 to +100. That is up 30 points from the previous 30 days (+20).

+72 Bullish 1 article

Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.

Articles

63
Show Summary
Show Bulletpoints
Detailed View
Very Bullish +85

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwritersโ€™ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

AI-generated analysis

Apogee Therapeutics, Inc. (Nasdaq: APGE) announced the closing of its public offering and the full exercise of the underwriters' option to purchase additional shares on March 26, 2026. The company sold 5,750,000 shares of its common stock at a public offering price of $70.00 per share, including an additional 750,000 shares purchased by underwriters. This transaction generated approximately $403 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses. The joint book-running managers for the offering were Jefferies, TD Cowen, Stifel, and Guggenheim Securities, with Wedbush PacGrow and BTIG serving as lead managers. An automatically effective shelf registration statement was filed with the SEC on August 12, 2024, and a written prospectus supplement forming part of an effective registration statement was utilized for the sale. Apogee Therapeutics is a clinical-stage biotechnology company focused on advancing optimized, novel biologics with potential best-in-class profiles in the largest inflammatory and immunology markets. The companyโ€™s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action while incorporating advanced antibody engineering to optimize half-life and other properties. With four validated targets in its portfolio, Apogee seeks to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. The companyโ€™s most advanced program, Zumilokibart (APG777), is being developed for the treatment of atopic dermatitis, asthma, and eosinophilic esophagitis, with a focus on the largest and one of the least penetrated inflammatory and immunology markets. The press release states that the company believes its broad pipeline and depth of expertise will allow it to deliver value and meaningful benefit to patients underserved by todayโ€™s standard of care. The offering was conducted in compliance with securities laws, and the distribution did not constitute an offer or solicitation of a sale in any jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the applicable state or local securities laws. Copies of the final prospectus supplement and accompanying prospectus were filed with the SEC and are available on the SECโ€™s website or through the designated underwriter contacts listed in the announcement.

๐Ÿ› Apogee Therapeutics closed its public stock offering, raising $403 million gross.

๐Ÿ’Š Proceeds fund development of biologics for Atopic Dermatitis and asthma targets.

โšก Zumilokibart (APG777) remains the company's most advanced inflammatory disease program.

๐Ÿ›๏ธ Apogee Therapeutics announced the closing of its underwritten public offering of common stock.

๐Ÿ’ฐ The company raised approximately $403 million in gross proceeds from the sale of 5,750,000 shares at $70 per share.

โšก The total amount includes full exercise of underwriters' options for an additional 750,000 shares.

๐Ÿค Jefferies, TD Cowen, Stifel, and Guggenheim Securities served as joint book-running managers for the deal.

๐Ÿ“‹ Wedbush PacGrow and BTIG acted as lead managers alongside the joint book-running team.

๐Ÿ“œ An automatically effective shelf registration statement was previously filed with the SEC on August 12, 2024.

๐Ÿฅ Apogee is a clinical-stage biotechnology company focused on inflammatory and immunology markets.

๐Ÿ’Š The company's primary target is Atopic Dermatitis, asthma, and Eosinophilic Esophagitis using novel biologics.

๐ŸŽฏ Zumilokibart (APG777) is the most advanced program in development for treating Atopic Dermatitis.

โš™๏ธ Apogee aims to overcome therapy limitations through advanced antibody engineering targeting four validated mechanisms.

๐Ÿ“… This offering was conducted via a written prospectus and supplement filed with the SEC for public access.

โš ๏ธ The company noted that the release does not constitute an offer to sell securities in jurisdictions where it is unlawful.

Bullish Signals
  • Closed public offering with $403 million in gross proceeds.
  • Raised capital at $70 per share including underwriter purchases.
  • Advanced program APG777 targets Atopic Dermatitis, asthma, and EoE.
  • Pipeline features four validated targets for best-in-class efficacy.
  • Novel antibodies optimize half-life and target established mechanisms.
Bullish Signals
  • Apogee Therapeutics successfully closed its public offering and exercised the underwriters' option for gross proceeds of $403 million, strengthening its financial position.
  • The company raised capital at a price of $70.00 per share through an underwritten offering including 5,750,000 shares plus additional shares purchased by underwriters.
  • Apogee's most advanced program, Zumilokibart (APG777), targets the largest and least penetrated I&I market of Atopic Dermatitis, alongside asthma and EoE.
  • The company possesses a broad pipeline with four validated targets to achieve best-in-class efficacy through monotherapies and combinations.
  • Apogee's novel antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms and optimizing half-life.
Risk Factors
  • The $403 million gross proceeds from the offering were realized at a public offering price of $70.00 per share, which represents a significant cash outlay for dilution to existing shareholders without immediately improving top-line revenue given the clinical-stage nature of the company.
  • Apogee Therapeutics remains a clinical-stage biotechnology company with no approved products and no commercial revenue, making it entirely dependent on successful future drug approvals and commercialization efforts after this major equity raise.
  • The primary development asset, Zumilokibart (APG777), faces significant execution risk as it targets Atopic Dermatitis (AD) and other I&I indications that are already crowded with incumbent therapies from major competitors like Eli Lilly, Novartis, and Regeneron.
  • Despite having four validated targets in its portfolio, the company's reliance on monotherapies and combinations requires achieving 'best-in-class' efficacy and dosing in highly competitive markets to gain meaningful market penetration.
  • The company continues to incur substantial operating expenses typical of pre-revenue biotech firms while advancing multiple novel biologics programs without any current product sales or generated cash flow.
Bullish +75

Broadridge Financial Solutions gets $2.4 million in tax breaks to keep 60 jobs in Islip Town

AI-generated analysis

Broadridge Financial Solutions has secured $2.4 million in additional property tax breaks from the Islip Town Industrial Development Agency to retain 60 jobs at its facilities in Edgewood and maintain operations against competition from other states. The town board unanimously voted to approve these incentives, which are part of a coordinated effort involving Suffolk County and New York State aimed at preventing the company from relocating its workforces. This local decision follows broader state support, including nearly $80 million in investment commitments and up to $40 million in grant money and tax credits from Empire State Development, totaling over $57 million in combined assistance across multiple jurisdictions. The tax breaks are structured as 12 years of property savings for the companyโ€™s locations at 120 Wilshire Blvd. and 300 Executive Dr., with a potential option to extend the period by three more years under certain conditions. In exchange for this financial support, Broadridge has pledged to invest $725,000 directly into the buildings and keep its workforce stable, reversing earlier plans that threatened up to 2,700 job cuts across New York State and a potential shift of operations to locations in California, Connecticut, Florida, Tennessee, and Texas. Financial records indicate the company reported an annual profit of $839.5 million on $6.9 billion in revenue as of June 30, highlighting its status as a major financial infrastructure provider that processes trillions of dollars in stock trades annually for Wall Street firms.

๐Ÿ› Islip Town approved $2.4M in property tax breaks to retain Broadridge's workforce.

๐Ÿค The deal includes commitments to invest nearly $80M and keep 2,200 regional jobs.

โš  Incentives were secured after the company explored relocating to other states.

๐Ÿ›๏ธ Broadridge Financial Solutions secured over $2 million in additional property tax breaks for two facilities in Islip Town on Tuesday.

๐Ÿค The town board voted unanimously to approve incentives that could potentially last up to 15 years to retain the company's workforce.

๐Ÿ“‰ This financial aid is part of a coordinated effort involving Suffolk County and New York State aimed at preventing Broadridge from relocating operations out of state.

๐Ÿข Broadridge serves as a major back-office function for Wall Street, delivering over 7 billion documents annually and processing trillions in daily stock trades.

๐Ÿ“Š The company recently reported an annual profit of $839.5 million on revenue of $6.9 billion for the year ended June 30 according to securities filings.

๐Ÿ’ฐ Governor Kathy Hochul previously announced a commitment for Broadridge to invest nearly $80 million and retain 2,200 jobs statewide in exchange for these incentives.

โš ๏ธ The company had previously considered closing facilities in Edgewood and Lake Success to save up to $270 million, which would have cut New York employment to about 750.

๐Ÿ”„ Management had explored moving work and jobs to other states including California, Connecticut, Florida, Tennessee, and Texas before securing this deal.

๐Ÿ’ต On Tuesday specifically, the Islip IDA granted $2.4 million in property tax savings over 12 years with a potential three-year extension.

๐Ÿ—๏ธ In return for the aid, Broadridge agreed to invest $725,000 in the buildings and retain 60 jobs at the 120 Wilshire Blvd. and 300 Executive Dr. locations.

๐Ÿ•ฐ๏ธ State records indicate the properties have been receiving tax aid since an agreement reached in 2012.

๐Ÿ—ฃ๏ธ Angie Carpenter, Islip supervisor and IDA board chair, praised Broadridge for providing high-quality jobs and reinforcing the town's reputation as an innovation hub.

๐Ÿ™ Broadridge spokesman Gregg L. Rosenberg thanked the IDA for recognizing competition from other states and taking steps to keep high-quality jobs on Long Island.

๐Ÿค This local action follows Suffolk IDA granting $17 million in tax breaks and Empire State Development providing up to $40 million in grants.

โšก The state Power Authority will next consider an application by Broadridge to extend low-cost electricity allocations it currently receives.

๐Ÿ’ก Current records show the Edgewood facilities receive 2,400 kilowatts of electricity specifically in return for retaining 1,713 jobs.

Bullish Signals
  • Broadridge secured $2.4M property tax breaks for Islip facilities.
  • Town board approved up to 15-year incentives for company retention.
  • Company retains 60 Edgewood jobs and invests $725K in buildings.
  • Governor Hochul announced nearly $80M investment to keep 2,200 NY jobs.
  • Broadridge delivers 7B documents annually and processes trillions in daily trades.
  • Firm reported $839.5M profit on $6.9B revenue last year.
  • Suffolk IDA awarded $17M tax breaks plus up to $40M grants.
Risk Factors
  • Previously considered closing four facilities to save $270 million over 10 years.
  • Tax application cited potential job transfers to California, Connecticut, Florida, Tennessee, and Texas.
  • Relocation or workforce cut could reduce Long Island jobs to roughly 750 statewide.
  • Retaining 2,200 jobs relies on government funding rather than organic growth.
Bullish Signals
  • Broadridge Financial Solutions secured an additional $2.4 million in property tax breaks for two facilities in Islip Town, reinforcing its position as one of Long Island's largest employers.
  • The town board unanimously approved incentives that could stretch up to 15 years, signaling strong local government support for retaining the company.
  • In return for these investments, Broadridge committed to retain 60 high-quality jobs in Edgewood and invest $725,000 directly into the buildings.
  • Statewide commitments include Governor Kathy Hochul announcing a nearly $80 million investment by Broadridge to keep 2,200 jobs across New York State.
  • The company continues to function as a critical Wall Street back office, delivering over 7 billion documents to shareholders annually and processing trillions of dollars in stock trades daily.
  • Recent financial filings show the company reported a robust profit of $839.5 million on revenue of $6.9 billion for the year ended June 30.
  • Broadridge is described as a fast-growing company with a global footprint, maintaining offices in Manhattan, Europe, Asia, and Australia.
  • Additional state support includes Suffolk IDA awarding $17 million in tax breaks and Empire State Development providing up to $40 million in grant money.
Risk Factors
  • Broadridge had previously considered closing one of four facilities in Edgewood and its Lake Success headquarters, a plan that would have saved the company up to $270 million over 10 years.
  • The company's tax break application from last year explicitly stated a consideration to transfer work and jobs to competitive states including California, Connecticut, Florida, Tennessee, and Texas.
  • Without the significant influx of state and local aid totaling over $60 million, Broadridge may still face pressure to relocate operations or reduce its Long Island workforce to roughly 750 employees statewide as originally proposed.
  • The company's ability to retain 2,200 jobs statewide relies on continued government funding, suggesting these positions are contingent on ongoing tax incentives rather than purely organic growth.
Neutral 0

Broadridge Financial Solutions, Inc. (BR) Presents at Wolfe Research FinTech Forum Transcript

AI-generated analysis

Broadridge Financial Solutions, Inc. (BR) presented at the Wolfe Research FinTech Forum on March 10, 2026, with Tom Carey, Corporate VP and President of Global Technology & Operations, speaking about the company's evolution and strategic direction. Carey, who joined the firm after earning a degree in artificial intelligence in 1992, highlighted his extensive tenure spanning 30 years during which he has managed various core functions including the NGO operations and global product management. He noted that the company is now actively launching new AI capabilities, referencing a desire to have started their career in AI in the present era rather than in the early 1990s when it was not yet commercially viable. Carey specifically discussed the GTO division, which serves wealth management and capital markets, indicating that his role oversees global technology and operations as well as product management capabilities worldwide. During the session, the focus shifted toward Broadridge's deep integration of artificial intelligence into its core business units to drive efficiency and innovation across the financial services sector. Carey emphasized that the company is moving beyond traditional processing models by leveraging generative AI and machine learning to enhance data analytics and decision-making for wealth management clients. He pointed out that these advancements allow Broadridge to provide more sophisticated insights and automated solutions, positioning the company as a critical infrastructure provider that transforms how financial institutions manage their operational backends. The presentation underscored the importance of long-term relationships with clients who rely on Broadridge's technology stack, noting that once integrated, switching providers is rarely an option due to the extensive data dependencies and complex system architectures involved. The implications of this strategy suggest a continued trend of consolidation in financial services technology where vendors like Broadridge capture increasing value through advanced AI-driven features rather than just basic transactional processing. By embedding AI at the core of their platform, Broadridge aims to deepen client retention and open new revenue streams related to predictive analytics and automated workflow optimization. The management team's confidence in these technologies indicates a belief that the market is ready for next-generation tools that reduce manual intervention and lower costs for wealth managers and capital market firms. As Carey concluded, the company remains committed to expanding its AI portfolio while maintaining the high standards of reliability and security required by financial institutions, ensuring they stay ahead of competitors who may be slower to adopt these transformative technologies.

๐Ÿ•ฐ๏ธ Tom Carey joined Broadridge in 1992 with an AI degree.

๐ŸŒ He now leads global technology and operations for wealth management.

๐Ÿ”ฎ He highlights that his early AI expertise was once undervalued.

- ๐Ÿ•ฐ๏ธ Tom Carey, Corporate VP of Global Technology & Operations, has worked at Broadridge for 30 years since graduating with an AI degree in 1992.

- ๐ŸŒ He currently oversees the Global Technology and Operations division, which serves wealth management and capital markets sectors.

- ๐Ÿ› ๏ธ His responsibilities include managing NGO operations and product management capabilities on a global scale.

- ๐Ÿ”ฎ Carey expressed enthusiasm about launching his career in AI today, noting that his original 1992 degree was effectively considered "useless" at the time.

- ๐Ÿ’ผ The presentation took place at the Wolfe Research FinTech Forum on March 10, 2026, introducing Tom Carey to analysts and investors.

Bullish Signals
  • Tom Carey leads Broadridge with 30 years of tenure.
  • His 1992 AI background positions the company as a forward-thinking leader.
  • GTO division manages wealth management, capital markets, and global products.
Bullish Signals
  • Tom Carey, President of Global Technology & Operations at Broadridge, highlights his 30-year tenure with the company, underscoring deep institutional knowledge and stability.
  • Mr. Carey brings an AI-focused educational background from 1992, positioning Broadridge as a forward-thinking leader in integrating artificial intelligence into its operations.
  • The company manages wealth management, capital markets, NGO operations, and global product capabilities through its Global Technology & Operations (GTO) division.